Telehealth Ketamine in California: Access, Laws, and What to Know

Quick Answer for California

As of 2026, California is broadly aligned with the federal Ryan Haight Act floor and standard state medical board telehealth rules. Telehealth ketamine care for California residents is governed by the Medical Board of California together with federal DEA rules under the Ryan Haight Online Pharmacy Consumer Protection Act. Patients should verify current requirements with the Medical Board of California before starting care, as state telehealth and controlled substance rules continue to evolve.

Is ketamine telehealth legal in California?

Telehealth ketamine is legal in California when prescribed under the federal Ryan Haight Act standard and the state medical board's telehealth rules. Ketamine is a Schedule III controlled substance, so prescribers must establish a valid provider-patient relationship — typically through a real-time audio-visual evaluation — and follow Medical Board of California documentation and standard-of-care expectations. Because telehealth controlled substance rules continue to change at both the federal and state level, verify the most current requirements with the Medical Board of California before scheduling care.

Does California Medicaid cover Spravato or telehealth ketamine?

Insurance coverage varies in California. Medi-Cal may cover Spravato with prior authorization; California is one of the more accommodating state Medicaid programs for FDA-approved esketamine, though off-label ketamine is patient-pay. Commercial insurance coverage for Spravato is more common when criteria for treatment-resistant depression are met, while compounded oral, sublingual, and IM ketamine for off-label uses is typically self-pay. Patients should contact their plan directly and ask about prior authorization requirements.

Can a nurse practitioner prescribe ketamine via telehealth in California?

California nurse practitioners with a 103 or 104 designation can independently furnish Schedule III controlled substances under defined conditions. This means the prescriber on a telehealth ketamine visit may be a physician, a nurse practitioner, or — depending on state scope-of-practice rules — a physician assistant. Patients can confirm a prescriber's license and scope of practice through the Medical Board of California or the appropriate California nursing board.

Do I need an in-person visit before telehealth ketamine in California?

As of 2026, federal DEA flexibilities extended during and after the COVID-19 public health emergency continue to allow many telehealth ketamine evaluations without a prior in-person visit, but this is subject to ongoing federal rulemaking. California generally does not require an additional state-specific in-person visit beyond federal expectations. Always verify current rules with the Medical Board of California before assuming a fully remote pathway is available.

Overview

California offers some of the broadest access to telehealth ketamine therapy in the United States. As the most populous state with nearly 39 million residents and a progressive healthcare regulatory environment, California has a large provider market, robust compounding pharmacy infrastructure, and well-established telehealth laws. Patients throughout California—from the Bay Area to the Central Valley to rural northern counties—can access ketamine treatment through licensed telehealth providers.

Regulatory Environment

California's telehealth framework is among the most comprehensive in the nation. The state's Telehealth Advancement Act of 2011 (AB 415) and subsequent legislation, including SB 1665, established broad telehealth practice standards. California law explicitly permits providers to establish a patient-provider relationship via telehealth without requiring an initial in-person visit.

The Medical Board of California (MBC) oversees physician practice, including telehealth consultations. The Osteopathic Medical Board of California regulates osteopathic physicians. Both boards recognize telehealth as a legitimate mode of healthcare delivery, provided the standard of care is maintained.

For controlled substances, California follows federal DEA requirements. Ketamine is classified as a Schedule III controlled substance under both federal and California law (California Health and Safety Code Section 11056). Prescribers must hold an active California medical license and DEA registration. California's Controlled Substance Utilization Review and Evaluation System (CURES), the state's PDMP, must be consulted before prescribing controlled substances.

California has not enacted ketamine-specific telehealth restrictions, but the MBC has emphasized that all telehealth prescribing must meet the same clinical standards as in-person care. The board has taken enforcement actions against providers who prescribe controlled substances without adequate evaluation, so proper documentation and clinical justification remain essential.

Provider Availability

Provider availability for telehealth ketamine in California is high. California's massive population and large physician workforce create a competitive telehealth marketplace. Virtually all major national telehealth ketamine platforms serve California patients, and many are headquartered in the state.

California's diverse geography means telehealth is especially valuable for patients in rural and agricultural regions—the Central Valley, the far north, the eastern Sierra, and the desert communities—where psychiatric specialists may be hours away. Even in urban areas like Los Angeles and San Francisco, telehealth offers convenience and shorter wait times compared to in-person ketamine clinics.

The state's participation in the Interstate Medical Licensure Compact and its large base of locally licensed providers means California patients generally have a wide selection of telehealth ketamine prescribers to choose from.

Compounding Pharmacy Access

California has one of the strongest compounding pharmacy sectors in the country. Multiple compounding pharmacies operate within the state, and the California State Board of Pharmacy rigorously regulates both in-state and nonresident pharmacies under the California Business and Professions Code.

The California Board of Pharmacy requires compounding pharmacies to comply with USP <795> and USP <797> standards. Out-of-state pharmacies must obtain a nonresident pharmacy license to ship compounded medications to California patients. The board has been proactive in enforcement, conducting inspections and taking action against noncompliant pharmacies.

California patients benefit from fast shipping times due to the state's proximity to major pharmacy distribution hubs. Most compounded ketamine orders arrive within one to three business days. However, patients in remote mountain or desert communities may experience slightly longer delivery windows.

Insurance and Cost Considerations

California has strong telehealth parity laws that require health plans to cover telehealth-delivered services on par with in-person services. However, this parity applies only to covered services—and compounded ketamine for psychiatric use remains off-label and is generally excluded from coverage (see our insurance coverage guide for details) by both private plans and Medi-Cal (California's Medicaid program).

Some California health plans may cover the telehealth consultation fee itself, even if the ketamine medication is not covered. Patients should check with their specific plan to determine whether mental health telehealth visits are a covered benefit.

Out-of-pocket costs for telehealth ketamine treatment in California tend to be on the higher end nationally, reflecting the state's elevated cost of living. Monthly medication costs typically range from $150 to $350, and consultation fees range from $150 to $300. Patients in the Bay Area and Los Angeles metro may encounter higher provider fees compared to providers serving patients statewide.

California law also provides certain patient protections regarding surprise billing and cost transparency that can benefit telehealth patients.

Key Considerations for California Patients

• Provider selection. California's large market means more options but also more variability in quality. Use our provider verification guide and check for any disciplinary history on the MBC's license verification portal.
• CURES compliance. Your provider is required to check the CURES PDMP before prescribing ketamine. This is standard practice and protects patient safety. Be transparent about all medications you are taking.
• Wildfire and disaster disruptions. California's wildfire seasons can disrupt mail delivery, power, and internet access. Have a contingency plan for medication supply and telehealth appointments during evacuation or power shutoff events.
• Cannabis interaction. California has legal recreational cannabis. If you use cannabis, disclose this to your ketamine provider, as there may be interactions or clinical considerations.
• Coastal vs. inland shipping. Inland California (Central Valley, desert regions) can experience extreme heat. Request temperature-controlled packaging if your medication ships during summer months.

References

• Medical Board of California — Physician licensing, telehealth practice standards, and license verification
• California State Board of Pharmacy — Pharmacy licensing, compounding regulations, and CURES PDMP
• California Telehealth Advancement Act (AB 415) — Foundational telehealth legislation for California